Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences Inc. is projected to experience significant revenue growth, with Ingrezza anticipated to achieve approximately $3 billion in sales by 2028, driven by robust double-digit prescription growth and ongoing market demand despite pricing challenges. The company's pipeline remains promising, with the potential to introduce a new medication every two years and current Phase 3 programs that are expected to enhance long-term financial performance. Additionally, the launch of Crenessity for classical congenital adrenal hyperplasia (CAH) is projected to contribute over $1 billion in peak revenues by 2030, underlining the company’s strong market position and growth prospects.

Neurocrine Biosciences Inc reported a disappointing non-GAAP EPS of $1.88 for 4Q25, missing consensus estimates significantly, which raises concerns about its financial performance. The company's revenue forecast for FY26 has been adjusted downwards to $2,729 million, reflecting a net price decline of approximately 5% and highlighting potential competitive risks in the market for its key product, Ingrezza. Additionally, increased R&D expenses driven by ongoing Phase 3 studies are expected to persist, contributing to a negative financial outlook as operational expenditures exceed earlier projections.